L-Hist Mont Syrup is a combination medication containing Levocetirizine 2.5 mg and Montelukast 4 mg, formulated for the management of allergic conditions. Levocetirizine is a potent, selective second-generation antihistamine that competitively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, itching, and urticaria associated with allergic rhinitis and chronic idiopathic urticaria. Montelukast is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors in the respiratory tract, leading to decreased bronchoconstriction, inflammation, and mucus production. The synergistic action of these agents provides effective relief from allergic rhinitis, asthma, and other hypersensitivity reactions by targeting different inflammatory pathways. L-Hist Mont Syrup is particularly beneficial in pediatric patients requiring symptom control of seasonal and perennial allergic rhinitis and asthma prophylaxis. The syrup formulation allows for ease of administration and accurate dosing in children. It is generally well tolerated, with a low incidence of sedation or adverse effects. However, caution is advised in patients with hepatic or renal impairment. L-Hist Mont Syrup should be used under medical supervision, and patients should be monitored for any hypersensitivity reactions or changes in clinical status during therapy.